Elan

116 results

Perrigo bought Elan eight months after the company had sold the Tysabri intellectual property.

Over-the-counter drug specialist Perrigo has once again hit out at the Revenue decision to pursue it for €1.64 billion in back taxes. Speaking to ana(...)

 A Perrigo  facility in  Michigan, US.  Perrigo bought Elan eight months after the Tysabri deal in a  so-called “inversion” deal. Photograph: Getty Images

North American stockbroking analysts have predicted that drugs giant Perrigo has an 80 per cent chance of a “favourable outcome” to the company’s €1.6(...)

Perrigo says it believes a tax assessment issued last November for the year 2013 is incorrect as a matter of law.   Photograph: Adam Bird/Bloomberg via Getty Images

Drugs group Perrigo has filed for judicial review of a Revenue decision that landed the company with one of the biggest tax bills in corporate history(...)

Theratechnologies aims to improve the quality of life for HIV patients. Photograph: iStock

A Canadian speciality pharmaceutical company has appointed Dublin man Conor Walshe as general manager of its European subsidiary. Theratechnologies,(...)

Immatics Biotechnologies chairman Peter Chambre and Alkermes director Shane Cooke are to join the board of UDG Healthcare as non-executive directors. Photograph: David Sleator

Healthcare services provider UDG Healthcare has appointed two new non-executive directors to its board. Immatics Biotechnologies chairman Peter Chamb(...)

Perrigo told shareholders it would  “timely file an appeal” with the Irish Tax Appeals Commission. Photograph: Adam Bird/Bloomberg via Getty Images

Pharma company Perrigo is understood to have filed an an appeal against a €1.64 billion Irish tax demand. The share price of group had fallen by more(...)

Perrigo, which acquired Irish pharma group Elan in late 2013, has signalled its intention to appeal the decision to the Tax Appeals Commission, the deadline for which falls on December 28th

Shares in pharma giant Perrigo rose more than 10 per cent at one point in New York on Wednesday, just ahead of the deadline for appealing its €1.64 bi(...)

Other exchequers jealously look at our soaring corporate revenues

There is an irony in the boost to our corporate tax bill over the last few years. Ireland, one of the countries in the firing line in terms of interna(...)

The bill relates to the sale in 2013 of rights to the company’s blockbuster multiple sclerosis drug Tysabri.

Shares in pharma group Perrigo slumped to a nine-year low on Friday after the company confirmed it faced a Revenue demand for €1.64 billion in back ta(...)

Perrigo noted that Revenue had moved just two months ahead of “the expiry of the applicable five-year statutory limitation period” for review of its 2013 tax bill.  Photograph: Bloomberg

There is a certain irony for drug group Perrigo that a move designed for its perceived tax advantage could end up undermining the finances of the comp(...)

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
  • Last »